Paul Tawa

Merck Canada Inc. (Canada)

Papers

1

Total Citations

3

H-Index

1

About

Paul Tawa is a researcher whose work has centered on the molecular mechanisms of apoptosis, particularly the role of caspase-3 in programmed cell death. His most notable contribution comes from a 2005 study that developed a novel active-caspase-3 enzyme-linked immunosorbent assay (ELISA) to quantitatively correlate fractional caspase-3 inhibition with apoptotic markers in NT2 cells. This work provided a critical methodological advance for precisely measuring caspase-3 activity in cellular models, offering a more nuanced understanding of how partial inhibition of this key executioner caspase impacts downstream apoptotic events. While his publication record reflects a focused, specialized contribution to cell biology, Tawa’s assay design has been cited in subsequent research exploring caspase regulation and therapeutic interventions for neurodegenerative and cancer-related apoptosis. His approach underscores the importance of correlating enzymatic activity with phenotypic outcomes, a principle that remains relevant for researchers studying cell death pathways. Though his citation count is modest, Tawa’s work represents a careful, foundational step in linking biochemical inhibition to cellular fate, demonstrating the value of precise quantitative tools in apoptosis research.

Research Focus

Key Achievements

1
H-Index
1
Papers
3
Total Citations
3
Avg Citations/Paper
🏆 Most Cited Paper
Correlating the fractional inhibition of caspase-3 in NT2 cells with apoptotic markers using an active-caspase-3 enzyme-linked immunosorbent assay
3 citations · 2005
📈 Most Prolific Year: 2005 (1 Papers)
🤝 Key Collaborators: 5
🏛 Institutions: Merck Canada Inc. (Canada)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago